Oxra-L (Dapagliflozin/Linagliptin)
| Active Ingredient | Dapagliflozin/Linagliptin |
|---|---|
| Indication: | Type 2 diabetes |
| Manufacturer: | Sun Pharmaceutical Industries Ltd |
| Strength | 10mg/5mg |
| Packaging | 10 Tablets in 1 Strip |
Oxra-L is a combination medication containing Dapagliflozin and Linagliptin, designed for the effective management of type 2 diabetes mellitus. Dapagliflozin is an SGLT2 inhibitor that helps lower blood sugar by removing excess glucose through urine, while Linagliptin is a DPP-4 inhibitor that boosts insulin secretion and reduces sugar production in the liver. Together, they offer a dual-action approach to blood sugar control, especially helpful for patients who do not achieve adequate control with single-drug therapy.
Oxra-L is taken once daily and can be used alone or alongside other diabetes treatments. It is generally well tolerated, with a low risk of hypoglycemia when not combined with insulin or sulfonylureas. For best results, use it as part of a broader diabetes management plan that includes diet, exercise, and regular blood glucose monitoring.








There are no reviews yet.